Bayer

Welcome to      
US Medical Affairs   
Hematology

Start Exploring

CONGRESS LIBRARY

CLINICAL TRIALS

RESOURCES

PRODUCT INFORMATION

ASKMED BY BAYER

Welcome to Bayer's Medical Affairs Hematology Platform!

For over 30 years, Bayer has been a leader in the development of therapies designed to help people with Hemophilia A all over the world.

Bayer introduced its first recombinant Factor VIII product in 1993 and has continued to innovate, developing four generations of products so far.

For over 30 years, Bayer has been a leader in the development of therapies designed to help people with Hemophilia A all over the world. Bayer introduced its first recombinant Factor VIII product in 1993 and has continued to innovate, developing four generations of products so far.

Bayer remains committed to advancing the care of people with hemophilia A through spreading awareness, as well as ongoing clinical research and real-world evidence generation. We invite you to explore educational resources and information on this website.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2023 Bayer. Bayer and the Bayer Cross, are registered trademarks for Bayer.

Site last updated 11/2023

Follow Us

Alt tag Alt tag
Alt tag Alt tag
Alt tag Alt tag
Alt tag

Copyright © 2023 Bayer  |  Bayer and the Bayer Cross are registered trademarks of Bayer.